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Abstract: Class B GPCR’s are activated by peptide ligands, typically 30-40 amino acid residues, that are involved in major physiological 
functions such as glucose homeostasis (glucagon and glucagon-like peptide 1), calcium homeostasis and bone turnover (parathyroid hor-
mone and calcitonin), and control of the stress axis (corticotropin-releasing factor). Peptide therapeutics have been developed targeting 
these receptors but development of nonpeptide ligands, enabling oral administration, has proved challenging. Allosteric modulation of 
these receptors provides a potential route to developing nonpeptide ligands that inhibit, activate, or potentiate activation of these recep-
tors. Here the known mechanisms of allosteric modulators targeting Class B GPCR’s are reviewed, particularly nonpeptide antagonists of 
the corticotropin-releasing factor 1 receptor and allosteric enhancers of the glucagon-like peptide-1 receptor. Also discussed is the poten-
tial for antagonist ligands to operate by competitive inhibition of one of the peptide binding sites, analogous to the Charniere mechanism. 
These mechanisms are then used to discuss potential strategies and management of pharmacological complexity in the future develop-
ment of allosteric modulators for Class B GPCR’s. 
Key Words: Allosteric, class B, G-protein-coupled receptor, secretin, corticotropin-releasing factor, nonpeptide, glucagon-like peptide, para-
thyroid hormone. 
INTRODUCTION 
  The class B G-protein-coupled receptor (GPCR) family is a 
small group of receptors, 15 in the human genome, that are acti-
vated by intermediate sized peptides of typically 30-40 amino acid 
residues (Table 1) [17, 21]. These peptides mediate a diverse array 
of important homeostatic processes and other physiological func-
tions, acting as hormones, autocrine factors and neuromodulators 
(Table 1). For example, parathyroid hormone and calcitonin recip-
rocally regulate calcium homeostasis and bone turnover, activating 
PTH1 and calcitonin receptors, respectively [54, 66]. Glucagon 
regulates hepatic glucose output [45, 52, 77], and post-prandial glu-
cose homeostasis is modulated by the incretin peptides glucagon-
like peptide-1 (GLP-1) and glucose-dependent insulinotropic pep-
tide (GIP) [18, 52, 77]. Corticotropin-releasing factor is the princi-
pal regulator of the stress axis, acting peripherally via activation of 
the hypothalamic-pituitary-adrenal (HPA) axis and centrally by 
means of modulating behavioral responses to stress [2, 20, 32, 81].  
  At least eight of the fifteen human Class B GPCR’s have re-
ceived attention as potential targets for the treatment of disease 
(Table 1). In some instances therapeutic agents have been devel-
oped from the peptides themselves. Calcitonin and parathyroid 
hormone are in clinical use for treatment of osteoporosis [54, 58]. A 
reptilian analogue of GLP-1, Exanatide (Byetta), has recently been 
developed as a mechanistically novel therapeutic for the manage-
ment of Type 2 diabetes [15, 19]. The major physiological and 
therapeutic function of these peptides has stimulated considerable 
understanding of their receptor binding and receptor activation 
mechanisms. Intrinsic to these mechanisms for Class B GPCR’s is 
the potential for allosteric regulation by nonpeptide ligands, which 
could aid the development of orally bioavailable modulators of 
Class B GPCR’s to circumvent practical and potential compliance 
issues with injections of the peptide therepeutics. Also intrinsic to 
the peptide binding mechanism is the potential for a modulator to 
act by competitive blockade of one of the peptide binding sites, a 
mechanism analogous to the Charniere model [69]. This mechanism 
challenges the utility of commonly-used analytical pharmacology 
methods to precisely define the mechanism of action of the modula-
tor. Here the peptide binding mechanisms are briefly reviewed, the 
modulator mechanisms evaluated with reference to specific exam-
ples, and then this information is applied to discuss methods and 
analytical issues in the future development of nonpeptide allosteric 
ligands targeting Class B GPCR’s. 
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TWO-DOMAIN MODEL OF PEPTIDE LIGAND INTERAC-
TION WITH CLASS B GPCR’S 
  Class B GPCR’s likely share a similar secondary and tertiary 
structure [17]. The extracellular N-terminal region, herein termed 
the N-domain, comprises approximately 100-160 amino acid resi-
dues. The NMR structure of the N-domain of the CRF2(b) receptor 
indicates a folded structure stabilized by three disulfide bonds, a 
hydrophobic core and an internal salt bridge [25]. The folded struc-
ture is comprised of -sheets in an orientation that is described as a 
short consensus repeat, or Sushi domain [25, 62]. The key residues 
involved in maintaining this structure are highly conserved 
throughout the Class B GPCR family, suggesting this structure is 
common to all Class B GPCR’s [25]. The remaining juxtamem-
brane domain of the receptor (J-domain) comprises seven predicted 
membrane-spanning  -helices with intervening intracellular and 
extracellular loops [17]. The structure of the J-domain has not been 
determined directly. It shares little primary structural homology 
with rhodopsin (for which the X-ray structure has been determined 
[60]) but mutagenesis and zinc-bridging studies suggest certain 
tertiary structure-stabilizing elements might be similar between 
Class A and Class B GPCR’s [22, 76]. 
  The orientation and mechanism of peptide interaction with 
Class B GPCR’s has been studied extensively using peptide struc-
ture-activity relationships (SAR) [7, 46, 79], receptor and ligand 
fragments [1, 38, 49, 61, 63, 79], chimeric receptors [3, 41, 74], 
site-directed mutagensis [33, 46], photochemical cross-linking [11, 
16, 51, 65], NMR structure determinations [4, 25, 55, 62] and mo-
lecular modeling [4, 11, 25, 65, 72]. Almost all of the data are con-
sistent with a low-resolution molecular orientation of binding in 
which the carboxyl-terminal portion of the peptide binds to the N-
domain of the receptor and the amino-terminal portion of the pep-
tide binds and activates the J-domain (Fig. 1A). For example, a 
chimeric peptide formed of the carboxyl-terminal portion of calci-
tonin and the amino-terminal portion of parathyroid hormone acti-
vates a chimeric receptor comprising the N-domain of the calcitonin 
receptor and J-domain of the PTH1 receptor [3]. The same orienta-
tion was inferred using the reciprocal chimeras [3], and with gluca-
gon/GLP-1 ligand and receptor chimeras [74]. The carboxyl-
terminal portion of the peptides typically form an -helix in binding 
to the N-domain of the receptor [55]. This interaction is of moder-
ate-to-high affinity (1-100nM) [1, 36, 38, 39, 61] and does not ap-
pear to be directly involved in receptor activation [14]. As a result, 
carboxyl-terminal fragments act as high-affinity antagonists [49, 68, 
87]. Interaction between the amino-terminal region of the peptide 
with the J-domain is of much lower affinity (in the high μM range). 
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signaling [50, 59, 78, 79]. Class B GPCR’s signal predominantly 
through GS-coupled pathways and, to a more limited extent, 
through Gq/11 and Gi family G-proteins. 
  The two-domain model provides a simple and tractable mecha-
nistic framework for interpreting peptide and allosteric modulator 
binding mechanisms [1, 33, 79]. One formulation of the model is 
presented in Fig. (1A). Peptide ligand binds the receptor N-domain, 
defined by the equilibrium association constant KN. This interaction 
provides an affinity trap, increasing the local concentration of the 
amino-terminal portion of the peptide in the vicinity of the J-
domain, overcoming the low-affinity of this interaction to enable 
significant binding to occur. This binding event is represented here 
as an isomerization between RLN, ligand bound to the N-domain 
alone, and RLNJ, ligand bound to both N- and J-domains (Fig. 1A). 
The strength of this interaction is described here by an isomeriza-
tion constant, KNJ, representing the RLNJ : RLN concentration ratio 
at equilibrium. 
  In order to understand mechanisms of allosteric modulation, it 
is instructive to consider the extent of peptide occupancy of N- and 
J-domains, under different conditions, for different receptors, and 
for different peptides binding the same receptor. In Fig. (1A), 
ligand occupancy of the N-domain alone is represented by RLN, and 
ligand occupancy of the J-domain is represented by RLNJ. The ex-
tent of receptor occupancy by the N-domain is largely dependent on 
the peptide concentration and KN. The fraction of peptide-bound 
receptors in which peptide is bound to the J-domain is dependent on 
KNJ. This binding energy varies between Class B GPCR’s and is 
dependent on the conformational state of the receptor. (Similar to 
most Class A GPCR’s the conformational state of Class B GPCR’s 
regulated by receptor-G-protein interaction [71], reflected in the 
higher agonist affinity at the G-protein coupled state (RG) com-
pared with the uncoupled state (R).) At the R state, the inferred 
value of KNJ is quite low for some Class B GPCR’s (e.g. <1 at 
PTH1 and CRF1 receptors [35, 38]). Under these conditions, the 
majority of peptide-occupied receptors have ligand bound only to 
the N-domain (Fig. 1B), with only a small fraction having ligand 
bound to J-domain (Fig. 1B). Importantly, under these conditions 
peptide ligand cannot saturate the J-domain of the receptor, even at 
ligand concentrations that saturate the receptor through occupancy 
the N-domain (Fig. 1B). Consequently, even at saturating peptide 
concentrations unoccupied J-domain will be available for other 
ligands to bind to, a significant property in understanding modula-
tor mechanisms (see below). Slightly stronger interaction with the 
Table 1.  Human Class B GPCR’s and Their Peptide Ligands 
Receptor  Peptide Ligand  Principal Biological Action  Major Disease  
Indication 
Peptide  
Therapeutic 
Refs. 
CRF1 
CRF 
UCN 1 
Stress responses 
Stress responses 
Depression 
(antagonist)    [2, 43, 92] 
CRF2 
UCN 1 
UCN 2 
UCN 3 
Stress responses  
Cardiac contractility 
Hearing 
Heart failure 
(agonist)   [2] 
GHRH  GHRH  Growth hormone release      [52, 77] 
GIP GIP  Insulin  secretion 
Type 2 diabetes 
(agonist)   [52,  77] 
Glucagon Glucagon  Glucose  homeostasis 
Type 2 diabetes 
(antagonist)   [52,  77] 
GLP-1  GLP-1  Insulin secretion  Type 2 diabetes (agonist)  Byetta (Exanatide)  [19, 52, 77] 
GLP-2  GLP-2  Gut mucosal growth      [52, 77] 
PTH1 
PTH 
PTHrP 
Ca
2+ homeostasis 
Developmental regulator 
Osteoporosis 
(agonist)  Forteo (PTH(1-34))  [5, 58, 73, 90] 
PTH2 TIP39 
Hypothalamic secretion, 
Nociception     [88] 
Secretin  Secretin  Pancreatic secretion      [52, 77] 
VPAC1 
VIP 
PACAP 
Neuroendocrine functions 
Neuroendocrine functions     [30,  77] 
VPAC2 
VIP 
PACAP 
Neuroendocrine functions 
Neuroendocrine functions 
   [30,  77] 
PAC1  PACAP  Neuroendocrine functions      [30, 77] 
Calcitonin Calcitonin  Ca
2+ homeostasis 
Osteoporosis 
(agonist) 
Miacalcin 
(calcitonin)  [54] 
Calcitonin/ RAMP1 
CGRP 
Amylin 
Vasodilation 
Feeding 
Migraine 
(antagonist)   [57,  67] 
Calcitonin / RAMP3  Amylin  Feeding      [57, 67] 
CL / RAMP1  CGRP  Vasodilation      [57, 67] 
CL / RAMP2  Adrenomedullin  Vasodilation      [57, 67] 
CL / RAMP3 
Adrenomedullin 
CGRP 
Vasodilation 
Vasodilation     [57,  67] 
Abbreviations: CRF - corticotropin-releasing factor; UCN - urocortin; GHRH - growth hormone-releasing hormone; GIP - glucose-dependent insulinotropic peptide; GLP - glucago n-
like peptide; PTH - parathyroid hormone; PTHrP - parathyroid hormone-related protein; TIP39 - tuberoinfundibular peptide of 39 residues; VIP - vasoactive intestinal peptide; PACAP 
- pituitary adenylate cyclase-activating polypeptide; CGRP - calcitonin gene-related peptide; RAMP - receptor activity modifying protein; CL - calcitonin receptor-like receptor. 170    Current Neuropharmacology, 2007, Vol. 5, No. 3  Sam R.J. Hoare 
J-domain (KNJ = 2) increases the fraction of occupied receptors in 
which peptide is bound the J-domain (Fig. 1C). Finally for some 
receptors a high value of KNJ has been inferred at the R state (e.g. 
30 for urocortin 2 interaction with the CRF2 receptor [36]). Under 
these conditions peptide is bound to the J-domain in almost all 
ligand-occupied receptors (Fig. 1D). G-protein interaction with the 
receptor likely increases the strength of ligand binding to the J-
domain, which can be represented by an increase of KNJ [38, 39]. 
As evident from comparing Fig. (1B-D), this effect of G-protein 
increases the fraction of occupied receptors in which ligand is 
bound to the J-domain. This inference is important in comparing 
modulator actions at R and RG states (see below). 
ALLOSTERIC MODULATORS OF THE CRF1 RECEPTOR 
  Allosteric modulators have been identified and developed for 
numerous Class A and Class C GPCR’s (see reviews in this issue). 
Mechanistic studies including analytical pharmacology, ligand SAR 
and receptor modification have elaborated general concepts and 
specific mechanisms of how allosteric ligands produce their modu-
latory effects. These methods have been applied to identify allos-
teric modulators of Class B GPCR’s. Low-molecular weight, non-
peptide allosteric modulators have been identified for CRF1, gluca-
gon and GLP-1 receptors (Fig. 2) [6, 24, 43-45, 75, 80, 86]. Mecha-
nistic studies, particularly with the CRF1 receptor, have demon-
strated that knowledge of the mechanism of peptide binding is 
highly useful in elaborating the mechanisms of allosteric modula-
tion of Class B GPCR’s. 
  Allosteric modulators of the CRF1 receptor have been studied in 
the most detail, in terms of ligand SAR [24, 43, 53], in vivo efficacy 
[28] and allosteric mechanism of action. Antagonism of central 
CRF1 receptors has been proposed as a potential novel mechanism 
for the treatment of anxiety, depression and other stress-related 
disorders, such as irritable bowel syndrome [28, 40, 56, 85]. This 
proposal has stimulated the discovery and development of a broad 
array of orally-available, CNS-penetrating nonpeptide antagonists 
that bind with high affinity (low nonomolar) to the CRF1 receptor. 
Prototypical examples include CP-154,526 [9], antalarmin [89], 
DMP696 [31], DMP904 [23], SR125543A [27] and NBI 30775 [8] 
(also known as R121919) (Fig. 2). Nonpeptide antagonists are ac-
tive in animal models of CRF- and environmentally-induced re-
sponses to stress [24, 28, 43, 53]. NBI 30775 has been tested in 
human subjects. This compound significantly reduced Hamilton 
depression and anxiety scores in severely depressed individuals in a 
small open-label Phase IIa clinical trial [92]. 
  The first evidence that nonpeptide antagonists of the CRF1 re-
ceptor act allosterically was provided by receptor mutation studies 
to identify the ligand binding site [48]. Mutation of two residues 
within the predicted membrane-spanning region of the receptor 
(H199V and M276I) reduced binding of the nonpeptide antagonist 
NBI 27914 without affecting binding of peptide agonists (e.g. 
CRF). This finding suggests the binding sites for nonpeptide an-
tagonist and peptide ligand are at least partially distinct. This hy-
pothesis is supported by subsequent findings that strongly imply 
M276 is proximal to the bound nonpeptide ligand [34]. In addition, 
the peptide binding determinants that have been identified to date 
are located within extracellular regions of the receptor – the N-
domain and the extracellular loops of the J-domain (reviewed in 
refs [12, 25, 34, 62]. Taken together these findings suggest CRF1 
receptor nonpeptide antagonists bind within the membrane-
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Two domain model of peptide interaction with Class B GPCR’s. A. Schematic representation of the two-domain model. The carboxyl-terminal 
portion of the peptide binds the extracellular N-terminal domain (N-domain) of the receptor, forming RLN, defined by the equilibrium constant KN. This inter-
action acts as an affinity trap, promoting interaction of the amino-terminal portion of the ligand with the juxtamembrane domain (J-domain) of the receptor, 
forming RLNJ. The J-domain interaction is defined by the isomerization constant KNJ, defining the RLNJ : RLN concentration ratio. B-D: Simulation of receptor 
occupancy, N-domain occupancy and J-domain occupancy by peptide ligand with varying strength of J-domain interaction. Occupancy of the receptor was 
defined by eq. 1 (Appendix), occupancy of the N-domain alone by eq. 2, and occupancy of the J-domain (with concomitant occupancy by the N-domain) by 
eq. 3. The parameter values used were: KN = 110
8 M
-1, [R]TOTAL = 100, and values of KNJ of 0.2 (B, weak J-domain interaction), 2 (C, moderate interaction) 
and 100 (D, strong interaction). Allosteric Modulators of Class B G-Protein-Coupled Receptors  Current Neuropharmacology, 2007, Vol. 5, No. 3    171 
spanning region of the J-domain and peptide ligands bind to sites 
further towards the extracellular face of the receptor, implying al-
lostetric interaction between peptide and nonpeptide ligand. 
  Radioligand binding studies are consistent with an allosteric 
interaction between nonpeptide antagonist and peptide ligands at 
the CRF1 receptor [37, 91]. In radioligand dissociation assays, non-
peptide ligands modulate the dissociation of radiolabeled peptides 
from the receptor and, reciprocally, peptide ligands modulate disso-
ciation of radiolabeled nonpeptides [37]. In equilibrium binding 
assays, peptide ligands do not fully inhibit specific binding of radio-
labeled nonpeptides [37, 91]. Nonpeptide ligands decrease the ap-
parent affinity of peptide ligands but this decrease of affinity ap-
proaches a limit as the concentration of nonpeptide ligand increases 
[37]. All of these features are consistent with the allosteric ternary 
model described for Class A GPCR’s such as muscarinic acetylcho-
line receptors [47, 84]. In this model, modulator can bind to the 
receptor occupied by endogenous ligand, and vice versa, forming a 
ternary complex between receptor, modulator and endogenous 
ligand. 
  The peptide-receptor interactions that are modulated by non-
peptide antagonists have been studied using receptor and peptide 
fragments [37, 38, 59, 64]. Binding of peptide agonists to the CRF1 
receptor is well-described by the two domain model described 
above and illustrated schematically in Fig. (1A) [25, 38, 64]. Non-
peptide binding determinants are borne largely if not exclusively by 
the J-domain;. nonpeptide antagonist affinity for a J-domain frag-
ment is not significantly different from that for the full-length re-
ceptor and the ligands do not displace radiolabed peptide binding to 
a N-domain fragment [38]. The peptide interaction that is blocked 
by nonpeptide antagonists appears to be that between the amino-
terminal region of the peptide and the J-domain of the receptor. 
Binding of a radiolabeled amino-terminal-truncated peptide ([
125I] 
astressin, a CRF(12-41) analogue) to the wild-type CRF1 receptor is 
not appreciably inhibited by nonpeptide ligands [37, 38, 64], and 
nonpeptide antagonists completely block CRF-stimulated activation 
of a J-domain fragment [38, 59]. Taken together these findings are 
consistent with the model in Fig (3A). In this model, CRF binding 
is described by the two-domain mechanism. Nonpeptide ligand 
binds within the membrane-spanning region of the J-domain, a site 
distinct from the CRF binding regions located further towards the 
extracellular face of the J-domain (Fig. 3A). Nonpeptide binding 
does not affect CRF binding to the N-domain, but allosterically 
inhibits CRF binding to the J-domain. Since CRF interaction with 
the J-domain is required for receptor activation, blocking this inter-
action with nonpeptide ligand effectively antagonizes CRF-
stimulated signaling. The behavior of this model, an extended vari-
ant of the allosteric ternary model, was simulated and rationalized 
as described in the Appendix and presented in Fig. (3B-E). In these 
simulations, nonpeptide ligand does not fully inhibit equilibrium 
binding of peptide ligand (Fig. 3B) and reciprocally peptide does 
not fully inhibit binding of nonpeptide (Fig. 3C). In radioligand 
dissociation experiments nonpeptide modulates dissociation of 
peptide ligand (Fig. 3D), and vice versa (Fig. 3E). 
  This model can explain an interesting feature of nonpeptide 
modulator action at the CRF1 receptor. In inhibiting peptide bind-
ing, nonpeptide ligands display a much greater allosteric effect 
(negative cooperativity) at the G-protein-coupled state of the recep-
tor (RG) compared with the uncoupled state (R) [37]. Nonpeptides 
near-fully inhibit peptide binding to the RG state but only partially 
inhibit peptide binding to R. This effect can be explained by a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Chemical structure of allosteric modulators of Class B GPCR’s. A. CRF1 receptor antagonists (SSR125543A [27]; antalarmin 
[89]; DMP904 [23]; NBI 30775 [8]; NBI 35965 [29]). For a review of CRF1 receptor antagonist chemical structure see ref [43]. B. Glucagon 
receptor antagonist [6, 13]. C. CGRP antagonist [75]. D. GLP-1 receptor antagonist [86]. E. GLP-1 receptor agonist [44]. 
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stronger peptide-J-domain interaction at the RG state compared 
with the R state. CRF binds with moderate affinity to the N-domain 
(approximately 50nM [38, 61]). At the R state, interaction with the 
J-domain is weak (KNJ <1), whereas at the RG state the J-domain 
interaction is much stronger (KNJ > 100) [38]. Consequently the 
extent of peptide occupancy of the J-domain is predicted to differ 
dramatically between R and RG states, with low J-domain occu-
pancy at the R state (e.g. Fig. 1B) and high occupancy at the RG 
state (e.g. Fig. 1D). Consequently, inhibition of J-domain occu-
pancy by nonpeptide ligand does not dramatically affect total recep-
tor occupancy by peptide at the R state, because only a minor frac-
tion the occupied receptors has peptide bound to the J-domain (Fig. 
1B). In contrast, at the RG state, inhibition of J-domain occupancy 
by nonpeptide ligand strongly reduces total receptor occupancy by 
peptide because almost all of the occupied receptors have peptide 
bound to the J-domain (Fig 1D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Allosteric modulation of peptide binding to Class B GPCR’s via the J-domain. A. Schematic representation of the model. Pep-
tide binding is described by the two domain model (Fig. 1A). Allosteric modulator binds the J-domain of the receptor at a site spatially dis-
tinct from the peptide binding regions, defined by the equilibrium constant KM. Binding of modulator allosterically regulates binding of pep-
tide to the J-domain, defined by the cooperativity factor , without affecting peptide binding to the N-domain. B-E. Manifestation of the 
model in binding assays for an allosteric inhibitor, simulated using equations in the Appendix. Binding parameters were: KN = 110
8 M
-1, 
[R]TOTAL = 100, KNJ = 2, KM = 110
8 M
-1 and  = 0.1 (allosteric inhibition, negative cooperativity). B. Modulation of equilibrium binding of 
peptide (L) by modulator (M), simulated using eq. 5, [L] = 110
-9 M. C. Modulation of peptide dissociation by modulator, simulated using 
eq. 7. The dissociation rate of peptide from the N-domain (k-N) was set at 0.02 min
-1. D. Modulation of equilibrium binding of modulator by 
peptide ligand, simulated using eq. 8, [M] = 210
-9 M. E. Modulation of modulator dissociation by peptide, simulated using eq. 12. The dis-
sociation rate of modulator (k-M) was set at 0.6 min
-1 and the dissociation rate of modulator from MRLNJ (k-M(L)) was set at 6.0 min
-1. Allosteric Modulators of Class B G-Protein-Coupled Receptors  Current Neuropharmacology, 2007, Vol. 5, No. 3    173 
NONPEPTIDE ALLOSTERIC MODULATORS OF OTHER 
CLASS B GPCR’S 
  Nonpeptide antagonists have been identified for glucagon [6, 
45], CGRP [75] and GLP-1 receptors [44, 86] that have been shown 
or inferred to act allosterically (Fig. 2B-E). The mechanisms by 
which these ligands modulate their receptors have not been estab-
lished in detail. Antagonism of the glucagon receptor has received 
interest as a potential mechanism for managing hyperglycemia in 
the treatment of Type 2 diabetes [45]. Numerous structural classes 
of high-affinity nonpeptide antagonists have been identified, with 
examples including L-168,049 (Fig. 2B), Bay 27-9955 and NNC 
25-2504 [45]. L-168,049 has been shown to allosterically modulate 
glucagon interaction with the glucagon receptor [6]. The ligand 
slows dissociation of [
125I]glucagon, and two mutations within the 
membrane-spanning region of the receptor reduce affinity of the 
antagonist without affecting binding of glucagon. These findings 
are potentially consistent with the ligand acting by a similar allos-
teric mechanism as that identified for nonpeptide antagonists of the 
CRF1 receptor (Fig. 3A). By contrast, a nonpeptide antagonist of 
the GLP-1 receptor, T-0632 (Fig. 2D), modulates the receptor by a 
different mechanism [86]. This low-affinity (1μM) ligand binds the 
N-domain of the GLP-1 receptor, at a site that appears at least par-
tially distinct from the peptide binding sites; W33S mutation in the 
N-domain decreases T-0632 affinity 120-fold without appreciably 
affecting binding of peptide ligand. Finally, a low-affinity (3μM) 
nonpeptide antagonist of the CGRP receptor (Fig. 2C) has been 
inferred to act allosterically from studies of chimeric receptors [75]. 
  Recently, the first allosteric agonist of a Class B GPCR was 
reported [44]. A representative of the compound class is shown in 
Fig. (2E). This nonpeptide ligand enhances the binding of [
125I]GLP-
1 to the GLP-1 receptor and directly activates the receptor, with 
potency of approximately 100nM. This direct agonist activity is 
apparent for the receptor expressed endogenously and is GLP-1 
receptor mediated: The modulator stimulates insulin release from 
pancreatic islets and perfused pancreas, and does not affect insulin 
release from islets isolated from GLP-1 receptor knockout mice 
[44]. Although the modulator enhances the binding of GLP-1 it 
does not detectably enhance the signaling activity of the peptide.  
POTENTIAL FOR ‘CHARNIERE’ TYPE MODULATION OF 
CLASS B GPCR’S 
  Inherent to the two-domain mechanism of peptide binding to 
Class B GPCR’s is a modulatory mechanism that can appear allos-
teric but which actually arises from competitive inhibition at one of 
the peptide binding sites. An explicit description of this type of 
phenomenon is the ‘Charniere’ effect [69]. In this mechanism an 
antagonist bears two functional groups, connected by a hinge-
region, one that binds the agonist binding site and the other that 
binds a distinct site not bound by the agonist. This model was de-
veloped to explain two unusual actions of some antagonists – per-
sistent blockade after washout and subsequent treatment with ago-
nist, and a time-course of the subsequent agonist response that is 
independent of the concentration of agonist [69, 70]. This model 
was applied to explain blockade of histamine responses [70], and 
blockade of acetylcholine by lachesine at muscarinc receptors of 
guinea pig ileum [69], and has been subsequently applied to other 
receptor systems, such as blockade of angiotensin-stimulated 
tachyphylaxis of rat uterine smooth muscle by a chlorambucil-
substituted peptide antagonist [83]. The Charniere concept can be 
expanded to include persistently-binding large agonists, which are 
blocked at their readily-reversible site of interaction by smaller 
antagonists. For example, salmeterol is a 2 adrenergic agonist that 
binds the endogenous-ligand binding site, blocked by classical an-
tagonists, and a second ‘exosite’ to which it persistently binds and 
which is not blocked by antagonists [26, 42]. A similar mechanism 
has also been used to explain the characteristics of xanomeline 
receptor interaction with the M1 muscarinc acetylcholine receptor 
[10].  
  Intrinsic to the two domain model is the potential for a Char-
niere-type modulation because a small ligand could competitively 
inhibit peptide binding to one of the two domains without affecting 
peptide interaction with the other. The behavior of one potential 
mechanism within this general model was evaluated. In Fig. (4A), a 
small ligand binds the J-domain at the same site that binds the 
amino-terminal region of peptide ligand, competitively inhibiting 
peptide-J-domain interaction. The small ligand does not affect bind-
ing of the carboxyl-terminal portion of the peptide to the N-domain 
of the receptor. Importantly, in this model there are no allosteric 
interactions between the small ligand and the peptide. Fig. (4B-E) 
and the Appendix describe the manifestation of this model in ligand 
binding experiments typically used to identify allosteric modula-
tors. In this simulation it was assumed the strength of peptide bind-
ing to the J-domain was moderate (KNJ = 2), such that occupancy of 
the J-domain represented a significant fraction of total receptor 
occupancy by peptide ligand (Fig. 1C). Under these conditions, the 
small ligand inhibits binding of the peptide but saturating concen-
trations of the small ligand only partially inhibit peptide binding 
(Fig. 4B). The residual receptor occupancy by peptide is comprised 
of peptide bound only to the N-domain of the receptor. In peptide 
ligand dissociation experiments, the small ligand can accelerate 
dissociation of the peptide ligand (Fig. 4C). This effect is a result of 
peptide only dissociating from the RLN state, rather than the RLNJ 
state, in the model. Dissociation of peptide from RLN is slowed by 
formation of RLNJ. The small ligand inhibits peptide binding to the 
J-domain of the receptor, preventing the formation of RLNJ that 
slows peptide dissociation, and consequently accelerating dissocia-
tion of peptide. In Fig. (4D), peptide inhibits small ligand binding 
but saturating concentrations of peptide do not fully inhibit small 
ligand binding. This effect is a result of the only partial occupancy 
of the J-domain by peptide ligand at saturating concentrations of 
peptide ligand (Fig. 1C); the remaining receptors are available to be 
bound by the small ligand. Finally, in dissociation experiments 
peptide ligand cannot affect the observed dissociation rate of the 
small ligand (Fig. 4E). The presence of pre-bound small ligand 
prevents binding of the peptide ligand to the J-domain, and peptide 
binding to the N-domain does not affect dissociation of the small 
ligand. 
  It is instructive to compare the potential consequences of this 
model, in which no allosteric interaction is involved, with the allos-
teric model presented in Fig. 3. The models are similar in that the 
modulating ligand binds the J-domain of the receptor but they differ 
in the mechanism by which the modulating ligand inhibits J-domain 
binding of the peptide (competitive in the direct interaction model, 
Fig. 4A, allosteric in the allosteric model, Fig. 3A). Both mecha-
nisms can result in partial inhibition of equilibrium binding of pep-
tide (Figs. 3B and 4B), acceleration of peptide dissociation from the 
receptor (Figs. 3C and 4C) and partial inhibition of modulator bind-
ing by the peptide (Figs. 3D and 4D). Consequently, identifying 
these patterns of behavior in binding assays is potentially insuffi-
cient, in the absence of other data, to define a ligand as an allosteric 
modulator. The principle difference between the models is that 
peptide ligand can modulate dissociation of an allosteric modulator, 
but not a competitive inhibitor of a peptide binding site. (Fig. 3E 
and 4E). In addition, two other results are only possible with the 
allosteric mechanism – enhanced binding of peptide by modulator 
(and vice versa), resulting from positive cooperativity, and slowing 
of peptide dissociation by modulator (see Appendix). These consid-
erations suggest that, for Class B GPCR’s, care should be employed 
in the interpretation of results from binding experiments typically 
used to define a compound as an allosteric modulator. As described 
below, mischaracterizing the mechanism of action of a ligand could 
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  The potential ambiguity between these mechanisms has arisen 
at least twice in the literature. In the first case, certain characteris-
tics of nonpeptide antagonists of the CRF1 receptor could poten-
tially be explained by both mechanisms; nonpeptide antagonists 
only partially inhibit peptide ligand binding, and peptides only par-
tially inhibit radiolabeled nonpeptide ligand binding [37]. Defining 
these compounds as acting allosterically was possible because the 
peptide ligands modulate radiolabeled nonpeptide dissociation from 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Charniere-type model of modulator interaction with Class B GPCR’s. A. Schematic representation of the model. In this model, 
a small ligand binds to one of the two sites of peptide interaction, in this specific example the J-domain. Binding of small ligand to this site, 
defined by the equilibrium constant KA, competitively inhibits peptide interaction with the J-domain but does not affect peptide binding to 
the N-domain. Note that in this model there is no allosteric interaction between the small ligand and peptide. B-E. Manifestation of the model 
in binding assays, simulated using equations in the Appendix. Binding parameters were: KN = 110
8 M
-1, [R]TOTAL = 100, KNJ = 2, and KA = 
110
8. B. Modulation of equilibrium binding of peptide (L) by small ligand (A), simulated using eq. 13, [L] = 110
-9 M. C. Modulation of 
peptide dissociation by small ligand, simulated using eq. 15. The dissociation rate of peptide from the N-domain (k-N) was set at 0.02 min
-1. 
D. Modulation of equilibrium binding of small ligand by peptide ligand, simulated using eq. 17, [A] = 210
-9 M. E. Modulation of small 
ligand dissociation by peptide, simulated using eq. 19. The dissociation rate of small ligand (k-A) was set at 0.6 min
-1. Note that this model 
does not allow peptide to modulate dissociation of small ligand, in contrast to the allosteric model (Fig. 3E). Allosteric Modulators of Class B G-Protein-Coupled Receptors  Current Neuropharmacology, 2007, Vol. 5, No. 3    175 
the receptor, nonpeptides slow dissociation of radiolabeled peptides 
[37], and perhaps most importantly mapping the binding sites by 
site-directed mutagenesis identified them as being spatially distinct 
on the receptor [34, 48]. In the second case, an amino-terminal 
analogue of parathyroid hormone (a modified PTH(1-14) fragment) 
only partially displaced binding of [
125I]PTH(3-34) [35]. Recipro-
cally, PTH(1-34) only partially inhibited interaction of the PTH(1-
14) analogue. This interaction between the two ligands was for-
merly described as allosteric [35] but in the absence of ligand dis-
sociation data this conclusion cannot be reliably drawn. The model 
described in Fig. (4A) is a more likely explanation for the data, 
given the location of the ligand binding sites [39, 50, 79]; PTH(3-
34) binds the N domain and weakly binds the J-domain, and 
PTH(1-14) analogues bind only to the J-domain. 
IMPLICATIONS OF CLASS B GPCR LIGAND BINDING 
MECHANISMS IN THE FUTURE DEVELOPMENT OF AL-
LOSTERIC MODULATORS 
  Peptide therapeutics have been developed that target Class B 
GPCR’s (Table 1), but their use can be complicated by the route of 
administration, typically injection. For example, Byetta is adminis-
tered by injection twice daily [19]. In addition, peptides of the size 
that bind Class B GPCR’s do not readily cross the blood-brain bar-
rier, limiting their use to peripheral disease indications. Allosteric 
modulation of Class B GPCR’s offers the opportunity of developing 
low molecular weight, nonpeptide agents that could be administered 
orally, and that could penetrate the blood-brain barrier to treat CNS 
disorders. Knowledge of the peptide binding mechanism could 
prove to be highly valuable in developing such ligands. 
  Broadly, two types of allosteric modulation could be employed 
for Class B GPCR’s – allosteric inhibition of peptide binding, and 
allosteric enhancement. Allosteric inhibitors could be developed as 
antagonists, targeting the CRF1 receptor as a potential treatment of 
stress disorders, the glucacon receptor for managing hyperglycemia, 
and the CGRP receptor as an alternative mechanism for treating 
migraine (Table 1). The two-domain model of peptide binding im-
plies that two different regions of the receptor could be targeted – 
the J-domain, blocking peptide-stimulated receptor activation (e.g. 
CRF1 receptor antagonists), and the N-domain, blocking the princi-
ple binding interaction between peptide and receptor. Allosteric 
enhancers could be developed to potentiate receptor signaling 
stimulated by the endogenous agonist. Allosteric enhancers of this 
type have been successfully developed for Class C GPCR’s, e.g. 
Cinacalcet, an enhancer of the calcium sensing receptor used to 
treat secondary hyperparathyroidism [82]. The two-domain model 
could accommodate at least two different enhancer mechanisms – 
enhancement of peptide affinity for the N-domain, increasing recep-
tor occupancy by the endogenous agonist and so enhancing the 
signaling output, and enhancement of peptide interaction with the J-
domain, directly enhancing the peptide interaction required for 
receptor activation. 
  Complexities of ligand binding to Class B GPCR’s could also 
impact specific stages of drug development. In high-throughput 
screening using a labeled peptide, the nature of the peptide binding 
mechanism could affect the outcome. Use of a peptide that binds 
predominantly to the N-domain could preclude identification of 
nonpeptide ligands that bind the J-domain. For example, [
125I] 
astressin binds to the N-domain of the CRF1 receptor and is not 
appreciably displaced by nonpeptide ligands that bind the J-domain 
[37, 64]. The use of [
125I]CRF enabled detection of the initial lead 
compounds because this radioligand binds strongly to the J-domain 
of the CRF1 receptor [38]. In optimizing leads, the nature of the 
nonpeptide mechanism might need to be considered to define the 
parameters used to define compound SAR. For example, if a non-
peptide partially blocks peptide binding by a Charniere mechanism,  
 
it would be fruitless to attempt to improve maximal inhibition of 
peptide binding. This parameter is defined by solely by the peptide 
binding energy for the J-domain, not by an allosteric effect. In se-
lecting compounds to test in vivo, the criteria need to be carefully 
considered. For example, a nonpeptide might only slightly inhibit 
binding by a Charniere mechanism but could fully antagonize the 
receptor if the interaction it blocks is required for receptor activa-
tion. The use of cellular signaling assays can provide an alternative 
means to address these issues, from high-throughput screening, 
through lead optimization and selection for in vivo testing. 
CONCLUDING REMARKS 
  Although the Class B GPCR family is relatively small com-
pared with the Class A family, at least half of the members of the 
Class B family are attractive therapeutic targets. Allosteric modula-
tion of these receptors represents a potential strategy for the devel-
opment of low molecular-weight agents as first-generation thera-
peutics (e.g. for the CRF1 receptor) or second-generation alterna-
tives to peptides already in clinical use (e.g. for the GLP-1 recep-
tor). The two-domain interaction of the endogenous peptides with 
Class B GPCR’s is highly amenable to allosteric modulation by 
nonpeptide ligands, through modulating the principle binding inter-
action with the N-domain or the principle activation interaction 
with the J-domain. Further understanding of these modulatory 
mechanisms should facilitate the future discovery and optimization 
of nonpeptide ligands targeting Class B GPCR’s. 
APPENDIX 
Formulation of the Two-Domain Model of Peptide Binding 
  Peptide binding to Class B GPCR’s can be represented by the 
two-domain model (Fig. 1A), in which the carboxyl-terminal por-
tion of the ligand binds the N-domain of the receptor, and the amino-
terminal region binds the J-domain [33]. This model assumes pep-
tide ligand (L) binds the receptor N-domain forming RLN, defined 
by the equilibrium association constant KN. This interaction concen-
trates L in the vicinity of the J domain, promoting formation of RLNJ. 
This interaction can be described as a reversible isomerization be-
tween RLN and RLNJ, defined by the isomerization constant KNJ 
([RLNJ] / [RLN]). The model assumes interaction between L and the 
J domain is weak, such that L binding to the J-domain alone (RLJ) 
does not contribute significantly to the overall occupancy of recep-
tor by L. 
The equilibrium concentration of ligand-bound receptor ([L]BOUND) 
is given by: 
L
TOTAL L
NJ N BOUND ] L [ 1
] R [ ] L [
] RL [ ] RL [ ] L [
K
K
+
= + =             (1) 
where KL = KN (1 + KNJ) and [R]TOTAL is total receptor concentra-
tion ([R]+[RLN]+[RLNJ]). The equilibrium concentration of RLN, 
ligand bound only to the N-domain, is given by: 
L
TOTAL N
N ] L [ 1
R] [ ] L [
] RL [
K
K
+
=                 (2) 
  The equilibrium concentration of RLNJ, in which L is bound to 
both the N-domain and J-domain, is given by: 
[RLNJ]=
[L]KNKNJ[R]TOTAL
1+[L]KL
                (3) 
  Dissociation of L from R is described by eq. 4, derived by as-
suming L only dissociates from RLN and isomerization between 
RLN and RLNJ is sufficiently rapid to be at steady-state during the 
dissociation phase. k-N is the rate constant for L dissociation from 
RLN and [L]BOUND = [RLN]+[RLNJ].  176    Current Neuropharmacology, 2007, Vol. 5, No. 3  Sam R.J. Hoare 
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By integration: 
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  Eq. 4 indicates the observed dissociation rate is slowed by iso-
merization of RLN to RLNJ, anticipated since the observed dissocia-
tion rate of L from the receptor is first-order with respect to RLN. 
Allosteric Modulators that Bind the J-domain of Class B 
GPCR’s 
  In this model, formulated in Fig. (3A), the modulator M binds a 
site on the J domain that is spatially distinct from the peptide bind-
ing site on the J-domain. Modulator binding does not affect binding 
of peptide to the N domain but can allosterically modulate peptide 
binding to the J-domain, defined by the cooperativity constant .  
  In Fig. (3B and C), the effect of M on the binding of L was 
simulated. Equilibrium binding of a fixed concentration of L was 
simulated in the presence of a range of concentrations of M (Fig. 
3B) using eq. 5, derived using the same logic used for eq. 1: 
 
[L]BOUND
[L]BOUND
[M]=0 =
1+[L]KL
KL

KL +[M]KNKM(1+KNJ)
1+[L]KL +[L][M]KNKM(1+KNJ)+[M]KM
                      (5) 
where [L]BOUND = [RLN]+[RLNJ]=[MRLN]+[MRLNJ],  
[L]BOUND
[M]=0
= [RLN]+[RLNJ]  and KL = KN(1 + KNJ) (see eq. 1). KM is 
the equilibrium association constant of M binding to R. In the pres-
ence of saturating concentrations of M, binding of L is defined by: 
[L]BOUND
[M]
[L]BOUND
[M]=0 =
1+[L]KN(1+ KNJ)
1+[L]KN(1+KNJ)
              (6) 
  Visual inspection of eq. 6 indicates that a saturating concentra-
tion of M does not reduce binding of L to zero when M is an allos-
teric inhibitor (<1). In addition, modulator can enhance binding of 
L (>1). 
  In Fig. (3C) the effect of M on dissociation of L from the recep-
tor was simulated using eq. 7. This derivation assumes, during the 
time course of L dissociation, a steady-state of isomerization be-
tween RLN and RLNJ, and between MRLN and MRLNJ, and no dis-
ruption of equilibrium between M and the receptor [47]. The deri-
vation also assumes M does not affect the dissociation rate of L 
from RLN. 
N N N
BOUND ]) MRL [ ] RL ([
d
] L [ d
 + = k
t
 
where k-N is the dissociation rate constant for L dissociation from 
RLN. The concentration of each L-bound component is given by: 
[RLN]=
KN[L]BOUND
KL +[M]KNKM(1+KNJ)
[MRLN]=
[M]KNKM[L]BOUND
KL +[M]KNKM(1+KNJ)
 
  By substitution and re-arrangement: 
d[L]BOUND
dt
=
KN(1+[M]KM)kN
KL +[M]KNKM(1+KNJ)
[L]BOUNDkN

[L]BOUND, t
[L]BOUND, t=0
= e
kobs.t      
 
                      (7) 
where kobs =
KN(1+[M]KM)
KL +[M]KNKM(1+KNJ)
kN
 
  In Fig. (3D and E), the effect of L on the binding of M was 
simulated. Equilibrium binding of a fixed concentration of M was 
simulated in the presence of a range of concentrations of L (Fig. 
3D) using eq. 8: 
 [M]BOUND
[M]BOUND
[L]=0 =
(1+[M]KM)1 +[L]KN(1+KNJ) ()
1+[L]KL +[M]KM 1+[L]KN(1+KNJ) ()
          (8) 
where  ] MRL [ ] MRL [ ] MR [ ] M [ NJ N BOUND + + = and  ] MR [ ] M [
0 [L]
BOUND =
=
. In 
the presence of saturating concentrations of L, binding of M is de-
fined by: 
[M]BOUND
[M]BOUND
[L]=0 =
1+KNJ +[M]KM(1+KNJ)
1+ KNJ +[M]KM(1+KNJ)
             (9) 
  Visual inspection of eq. 9 indicates that negative cooperativity 
(<1) decreases binding of M, since the numerator is less than the 
denominator, and reciprocally positive cooperativity (>1) in-
creases binding of M. 
  In Fig. (3E), the effect of L on dissociation of M was simulated. 
This derivation makes a number of simplifying assumptions to en-
able an explicit derivation. As described in ref [47], allosteric 
modulation of ligand dissociation can result in complex effects on 
the ligand dissociation curve depending on the relative kinetics of 
the two ligands. The following derivation assumes that dissociation 
of L from RLN is much slower (30-fold) than M dissociation from 
MR, that the kinetics of isomerization between RLN and RLNJ are 
rapid compared with L dissociation from RLN, and that L binding to 
the J domain accelerates dissociation of M [47]. Under these condi-
tions, MR behaves as a distinct population from the peptide-bound 
species MRLN and MRLNJ. Dissociation of M from MR is de-
scribed by: 
t k
t t e
.
0  
M ] MR [   ] MR [
 
= =               (10) 
where k-M is the rate of dissociation of M from MR. Dissociation of 
M from MRLN and MRLNJ is described by: 
 
d[ M R L N]+[MRLNJ] ()
dt
= [MRLN]kM +[MRLNJ]kM(L)
=
[MRLN]+[MRLNJ] () kM +KNJkM(L) ()
1+KNJ
 
() ()
t k
t t e
M(L)obs.
0 NJ N NJ N ] MRL [ ] MRL [ ] MRL [ ] MRL [
 
= + = +          (11) 
where k-M(L) is the dissociation rate of M from MRLNJ and where: 
kM(L)obs =
kM +KNJkM(L)
1+KNJ
 
  Dissociation of M in the presence of L is the sum of the two 
exponential equations 10 and 11, as follows: 
 [M]BOUND, t = [RM]t=0e
kM .t + [MRLN]+[MRLNJ] () t=0 e
kM(L)obs.t  

[M]BOUND, t
[M]BOUND, t=0
=
e
kM .t +[L]KN(1+KNJ)e
kM(L)obs.t
1+[L]KN(1+KNJ)
          (12) 
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Charniere-Type Model Applied to Class B GPCR’s 
  In the Charniere model, an antagonist ligand can bind two sites, 
the first a ‘specific’ site that can be bound by agonist and the sec-
ond an ‘unspecific’ site that can only be bound by the antagonist 
[69]. Two separate, hinged regions of the antagonist molecule bind 
the two distinct sites. This model can be applied to Class B 
GPCR’s. The formulation (Fig. 3A) only considers ligand binding, 
disregarding agonistic or antagonistic properties of the ligands. 
Full-length peptide ligand (L) binds according to the two-domain 
model (Fig. 1A, eqs. 1-4). A second small ligand (A) binds the 
peptide-binding site on the J domain, defined by the equilibrium 
association constant KA. This interaction competitively inhibits 
peptide binding to the J-domain of the receptor but does not affect 
peptide binding to the N-domain. Importantly, there is no allosteric 
interaction between the two ligands in this model. 
 In  Fig.  (4B and C), the effect of A on the binding of L was 
simulated. Equilibrium binding of a fixed concentration of L was 
simulated in the presence of a range of concentrations of A (Fig. 
4B) using eq. 13: 
) 1 )( ] A [ 1 ( ) ] A [ 1 ( ] L [
) ] L [ 1 )( ] A [ 1 (
] L [
] L [
NJ A A NJ L
L A NJ
0 [A]
BOUND
BOUND
K K K K K
K K K
+ + + + +
+ + +
= =
        (13) 
  
where [L]BOUND=[RLN]+[RLNJ]+[RLNAJ], [L]BOUND
[A]=0  =[RLN]+[RLNJ] 
and KL = KN(1+KNJ) (see eq. 1). In the presence of saturating con-
centrations of A, binding of L is defined by: 
NJ L
L
0 [A]
BOUND
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] L [ 1
] L [ 1
] L [
] L [
K K
K
+ +
+
= =
                (14) 
  Visual inspection of eq. 14 indicates that saturating concentra-
tions of A do not reduce L binding to zero. Eq. 14 also indicates 
that A can inhibit binding of L but cannot enhance binding of L, 
since the denominator is the sum of the numerator and KNJ.  
  In Fig. (4C) the effect of A on dissociation of L from the recep-
tor was simulated using eq. 15. This derivation assumes, during the 
time course of L dissociation, a steady-state of isomerization be-
tween RLN and RLNJ and no disruption of equilibrium between A 
and the receptor [47]. 
d[L]BOUND
dt
= ([RLN]+[RLNAJ])kN
 
where k-N is the dissociation rate constant for L dissociation from 
RLN. By substitution and re-arrangement: 
d[L]BOUND
dt
= [L]BOUND
(1+[A]KA)kN
1+ KNJ +[A]KA

[L]BOUND  t
[L]BOUND (t=0)
= e
k(obs)t
where k(obs) =
1+[A]KA
1+ KNJ +[A]KA
kN
          (15) 
  In the presence of saturating concentrations of A, the observed 
dissociation rate of L is given by: 
k(obs)
[A] = kN                   ( 1 6 )  
  Eq. 16 indicates that A accelerates the observed dissociation of 
L, anticipated since A increases the level of RLN by inhibiting its 
isomerization to RLNJ. Saturating concentrations of ligand A in-
crease the observed rate to that for dissociation from RLN because 
A competitively inhibits formation of RLNJ. 
 In  Fig.  (4D and E), the effect of L on the binding of A was 
simulated. Equilibrium binding of a fixed concentration of A was 
simulated in the presence of a range of concentrations of L (Fig. 
3D) using eq. 17:  
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where [A]BOUND =[RAJ]+[RLNAJ] and [A]BOUND
[L]=0
=[RLN]+[RLNJ]. In 
the presence of saturating concentrations of L, binding of A is de-
fined by: 
NJ A
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BOUND
] A [ 1
] A [ 1
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  Visual inspection of eq. 18 indicates that saturating concentra-
tions of L do not reduce A binding to zero. Eq. 18 also indicates 
that L can inhibit binding of A but cannot enhance binding of A, 
since the denominator is the sum of the numerator and KNJ. 
 In  Fig.  (3E) dissociation of A from the receptor was simulated 
using Eq. 19: 
d[A]BOUND
dt
= ([RAJ]+[RLNAJ])kA
= [A]BOUNDkA

[A]BOUND t
[A]BOUND(t=0)
= e
kAt              (19) 
where k-A is the dissociation rate constant for A dissociation from 
RAJ. From the derivation and Fig. 4A) it is evident that L cannot 
affect dissociation of A because binding of L to form RLNAJ does 
not affect the dissociation rate of A from RAJ, and RAJ cannot iso-
merize to a different bound state. 
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